Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Publication alerts by email
Advertising
Job board
Contact
100th anniversary
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Author's Takes
Reviews
Reviews
View all reviews ...
Review Series
Vascular Malformations (Apr 2024)
Lung inflammatory injury and tissue repair (Jul 2023)
Immune Environment in Glioblastoma (Feb 2023)
Korsmeyer Award 25th Anniversary Collection (Jan 2023)
Aging (Jul 2022)
Next-Generation Sequencing in Medicine (Jun 2022)
New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
View all review series ...
Viewpoint
Collections
In-Press Preview
Commentaries
Research Letters
Letters to the Editor
Editorials
Viewpoint
JCI This Month
Top read articles
Clinical Medicine
Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts.
P D Cotter, … , L Wong, D F Bishop
P D Cotter, … , L Wong, D F Bishop
Published October 1, 1995
Citation Information:
J Clin Invest.
1995;
96(4)
:2090-2096.
https://doi.org/10.1172/JCI118258
.
View:
Text
|
PDF
Research Article
Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts.
Text
PDF
Abstract
Authors
P D Cotter, A May, E J Fitzsimons, T Houston, B E Woodcock, A I al-Sabah, L Wong, D F Bishop
×
Other pages:
2090
2091
2092
2093
2094
2095
2096
Other pages:
2090
2091
2092
2093
2094
2095
2096